GDPD3 and chronic myelogenous leukemia, BCR-ABL1 positive: Strikingly, recipient mice that harbored Gdpd3-deficient CML stem cells and were treated with the TKI dasatinib showed a decrease in disease relapse even after a first-round of BMT.